Ovarian carcinoma

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This phase 2 trial is investigating whether adding an experimental DNA-based therapy called ELENAGEN to the chemotherapy drug gemcitabine can help people with platinum-resistant ovarian cancer. The study will compare the combination against gemcitabine alone, measuring how long p…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responde…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study looked at whether giving heated chemotherapy directly into the abdomen during a second-look surgery is possible for people with ovarian, fallopian tube, or peritoneal cancer. Ten participants who had already received standard treatment were enrolled. The goal was to se…

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …

This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…

This trial tests an experimental drug called enfortumab vedotin, which is designed to seek out and destroy cancer cells that have a specific protein called Nectin-4 on their surface. The study includes people with metastatic urothelial cancer (a type of bladder cancer) and other …

This phase II trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) improves outcomes for people with advanced stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. The study aims to s…

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes …

This completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …

This large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…

This phase 2 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep cancer from growing in people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. After initial chemotherapy with paclitaxel, 20 participants received pembrolizuma…

This early-phase trial tested a new treatment called Radspherin for women with ovarian cancer that has returned and spread in the abdomen. Radspherin consists of tiny radioactive particles injected directly into the belly after surgery to remove visible tumors. The study involved…

This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer…

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by mai…

This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…

This study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that stopped responding to platinum chemotherapy and had previously taken PARP inhibitors. The goal was to see if the combo could control the cancer for at least 6 months. The…

This study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that had stopped responding to platinum-based chemotherapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants took the drugs by…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This early-phase study tested whether adding a new drug called LDE225 to standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen participants were monitored for side effects and to find the best dose. …

This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients re…

This study looked at how effective and safe niraparib is for Korean women with epithelial ovarian cancer. It included 850 patients who took niraparib as maintenance therapy or as a later treatment. Researchers measured how long patients lived without their cancer getting worse an…

This early-phase study tested whether adding simvastatin, a common cholesterol-lowering drug, to standard chemotherapy could slow cancer progression in women with recurrent platinum-sensitive ovarian cancer. 18 participants took simvastatin alongside carboplatin and liposomal dox…

This study tested a new drug called IMP4297 in 93 women with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has come back after at least two prior treatments. The goal was to see if the drug can shrink tumors or slow the cancer's growth. The drug is taken as …

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 alone could shrink tumors and how safe it was. Participants had already tried at least three other…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also loo…

This study tested whether giving the immunotherapy drug nivolumab directly into the abdomen is safe after extensive surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. 22 adults with recurrent ovarian, peritoneal, or fallopian tube cancer took part. The goal was …

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested whether zafirlukast, an asthma drug, can slow or stop ovarian cancer in people whose only sign of relapse is a rising CA-125 blood marker. Only 5 participants were enrolled. The main goal was to see if the drug could lower CA-125 levels by at least half for a mo…

This study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The r…

This Phase 1 trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in complete remission. The treatment is made from each patient's unique tumor mutations an…

This early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …

This early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, whil…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…

This phase 2 trial tested whether adding an experimental drug (MK-4830) to standard chemotherapy and pembrolizumab (Keytruda) could better shrink high-grade serous ovarian cancer before surgery. 160 participants with stage III or IV disease received either the standard regimen or…

This Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…

This Phase 3 trial tested whether adding the experimental drug BD0801 to standard chemotherapy can help women with recurrent ovarian cancer that no longer responds to platinum-based treatments. The study enrolled 421 participants and compared the combination to chemotherapy alone…

This phase II trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with stage IV ovarian cancer. 91 participants received either chemo alone or chemo plus pembrolizumab, followed by surgery. The goal was t…

This early-phase trial tested the combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find a safe dose and check for side effects. Researchers also lo…

This study looked at whether fluid collected from behind the vagina (culdocentesis) can help diagnose ovarian cancer. Researchers measured tumor markers CA-125 and HE4 in the fluid of 52 women scheduled for surgery. They also checked a urine sample for estrogen ratios. The goal w…

This study aimed to find DNA markers in the blood that could help detect a serious type of ovarian cancer early. Researchers compared DNA from women with and without ovarian cancer to identify differences. The goal is to develop a simple blood test for earlier diagnosis. Ten wome…

This study tests whether using a special monitor (ANI) during ovarian cancer surgery to guide pain medicine can lower the chance of chronic pain three months after the operation. About 126 women having open surgery for ovarian cancer will be randomly assigned to standard care or …

This study tested whether giving heated chemotherapy directly into the abdomen during surgery can improve quality of life for people with advanced ovarian, fallopian tube, or peritoneal cancer. Fifty participants received the treatment after standard chemotherapy. Researchers mea…

This study tested whether bupropion, a medication that affects brain chemicals, can improve low sexual desire in women who have had breast or gynecologic cancer. About 230 women took either bupropion or a placebo pill for 9 weeks. The main goal was to see if their self-reported s…

This study tested a web-based program to improve quality of life and reduce stress in ovarian cancer survivors. 326 women participated, comparing a mindfulness program to a healthy lifestyle program. The goal was to see if the online programs could help with stress, anxiety, mood…

This early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…

This study checks for muscle loss (sarcopenia) in 25 women with advanced ovarian cancer before they start chemotherapy. Using CT scans, researchers want to see how common this condition is and if it affects treatment timing. The goal is to better understand how muscle health rela…

This study asks whether measuring circulating endothelial cells (CECs), cells shed from blood vessel walls, can predict how well ovarian cancer patients respond to standard chemotherapy with or without bevacizumab. Researchers will use a standardized flow cytometry method to coun…

This study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV c…

This study looks at how proteins in the blood change in women with ovarian cancer as they go through standard treatment. Researchers collected blood samples before surgery, after surgery, and after chemotherapy to see if these protein shifts could give a fuller picture of how the…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …

This study looked at how doctors in Russia treat a specific type of ovarian cancer called HRD-positive. Researchers collected information from 414 patients to understand what treatments they received and how they fared. The goal was to describe real-world practice, not to test a …

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This study reviewed medical records of 51 women with ovarian, fallopian tube, or peritoneal cancer who received the drug rucaparib in real-world clinics, not just in strict trials. Researchers looked at patient history, side effects, dosing, and how long the drug kept cancer from…

This study looked at how behavioral factors, hormones, and natural body chemicals might influence tumor growth in ovarian cancer. Researchers studied 613 women with ovarian cancer to understand these connections. The goal was to gather knowledge, not to test a treatment.

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This completed study looked at how muscle energy use differs in women with ovarian or endometrial cancer who are losing weight, depending on their body mass index (BMI). Researchers took blood samples, muscle biopsies, and fat tissue from 70 women during surgery. The goal was to …

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…

This study tested whether saliva samples can be used to remotely monitor cytomegalovirus (CMV) infection in people receiving treatment for ovarian cancer. Researchers compared saliva and blood samples from 49 participants, collected either at the clinic or at home. The goal was t…

This study measured 14 trace elements in blood samples from 40 women with endometriosis, ovarian cancer, endometrial cancer, or healthy controls. Researchers wanted to see if levels of elements like iron, selenium, or lead differ between these groups. The goal is to find clues th…

This study looked back at medical records of 342 women in Europe with advanced ovarian cancer and a BRCA gene mutation. All had taken the drug olaparib (Lynparza) as their first maintenance treatment after initial chemotherapy. Researchers tracked how long patients lived without …